Abstract
Primary penile lymphoma is extremely rare. Here we report the case of a 67-year-old man with the chief complaints of difficulty in urination and priapism, who was eventually diagnosed with primary malignant lymphoma of the penis. Pathological examination of excision biopsy of the left inguinal lymph node revealed malignant CD20+ diffuse large B-cell lymphoma. We treated this patient with a systemic rituximab-chemotherapy regimen and obtained good results, in terms of both functional and cosmetic outcomes. Soluble interleukin-2 receptor was a useful tumor marker for evaluating the therapeutic effect. The patient has been in remission for 10 months after the discontinuation of chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gallardo F, Pujol RM, Barranco C et al (2009) Progressive painless swelling of glans penis: uncommon clinical manifestation of systemic non-Hodgkin’s lymphoma. Urology 73:929
Wang HT, Lo YS, Huang JK (2003) Primary lymphoma of the penis. J Chin Med Assoc 66:379–381
Arena F, di Stefano C, Peracchia G et al (2001) Primary lymphoma of the penis: diagnosis and treatment. Eur Urol 39:232–235
Kim HY, Oh SY, Lee S et al (2008) Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy. Acta Haematol 120:150–152
Madeb R, Rub R, Erlich N et al (2007) Long-standing priapism as presentation of lymphoma. Am J Hematol 82:87
Schroeder-Printzen I, Vosshenrich R, Weidner W et al (1994) Malignant priapism in a patient with metastatic prostate adenocarcinoma. Urol Int 52:52–54
Takeshita T, Asao H, Ohtani K et al (1992) Cloning of the gamma chain of the human IL-2 receptor. Science 257:379–382
Ennishi D, Yokoyama M, Terui Y et al (2009) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (R-CHOP) therapy. Ann Oncol 20:526–533
Goto H, Tsurumi H, Takemura M et al (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131:73–79
Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006
Pfreundschuh M, Trümper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391
Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
Conflict of interest
No author has any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hamamoto, S., Tozawa, K., Nishio, H. et al. Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy. Int J Clin Oncol 17, 181–184 (2012). https://doi.org/10.1007/s10147-011-0273-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-011-0273-8